Global Myasthenia Gravis Drugs Market 2017-2021
About Myasthenia Gravis Drugs
Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.
Technavio’s analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.Covered in this report
The report covers the present scenario and the growth prospects of the global myasthenia gravis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of myasthenia gravis drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Myasthenia Gravis Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global myasthenia gravis drugs market: Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Shire, and Valeant Pharmaceuticals
Other Prominent Vendors in the market are: Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, and Novartis
Commenting on the report, an analyst from Technavio’s team said: “The high unmet medical need in the market has driven the emergence of new entrants, which are extensively conducting R&D activities to bring new products to the market. For instance, Curavac, Novartis, Cytokinetics, and Catalyst Pharmaceuticals are few of the potential vendors that are anticipating new approvals during the forecast period. Curavac is currently investigating CVMG101, an immunotherapy, for the potential treatment of myasthenia gravis. The drug candidate is in Phase Ib development stage. CVMG101 already received orphan drug designation from the US FDA and European Medicines Agency (EMA) in 2011 and 2009, respectively. Therefore, the product has an added advantage in gaining approval soon.”
According to the report, myasthenia gravis is the common disorder of neuromuscular transmission. The presence of large patient pool with myasthenia gravis is expected to fuel the market growth. The data estimates suggest that out of the existing patient pool in the US, approximately 15%-20% of people will experience a myasthenic crisis (a complication of myasthenia gravis resulting in severe muscle weakness, leading to respiratory failure). Three-fourths of these cases experience their first crisis within two years of diagnosis. Further, the disease is increasingly affecting the pediatric population, which will, in turn, increase the overall patient pool, thereby fueling the market growth. For instance, the incidence in the pediatric population is estimated to be between 1 and 5 cases per million. It is further estimated that between 10% and 15% of the myasthenia gravis cases occur in the pediatric population. Such rising cases with myasthenia gravis will certainly drive the market growth.
Further, the report states that the growing preference for substitutes such as thymectomy could hinder the growth prospects in the market. Thymectomy is mandatory in individuals with thymoma and is recommended as an alternative for non-thymomatous individuals with generalized myasthenia gravis. Particularly in individuals with acetylcholine antibodies and younger than 60 years, to enhance the likelihood of remission or improvement. Thymectomy therapy offers long-term benefit to an individual by reducing or stopping the existing chronic medical therapies. In addition, there has been growing support from healthcare organizations to opt for thymectomy. For instance, in August 2016, in a global study of myasthenia gravis (partially funded by National Institutes of Health), researchers found that surgical removal of thymus reduced individual's weakness and their need for immunosuppressive drugs. On an average, the researchers stated that the combination of surgery and prednisone treatment minimized overall muscle weakness greater than prednisone treatment alone. Although surgery is associated with higher costs, it could reduce the length of hospitalization. Further, thymectomy rarely causes any adverse effects. This indicates that surgery would affect the adoption rates of existing drugs in the market.
Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Shire, Valeant Pharmaceuticals, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis.